Andrew X. Zhu
朱秀轩
MD, PhD
Director, Liver Cancer Research Program; Professor of Medicine肝癌研究项目主任；内科学教授
👥Biography 个人简介
Andrew Zhu is a Harvard-based HCC drug developer who led landmark trials of regorafenib (RESORCE) and ramucirumab (REACH-2), the first biomarker-selected trial in HCC. His research on anti-angiogenic mechanisms and combination strategies has fundamentally advanced the HCC treatment portfolio.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
REACH-2 – Ramucirumab Biomarker Trial
Led REACH-2, the first positive biomarker-selected phase III trial in HCC, establishing ramucirumab for AFP ≥400 ng/mL patients, demonstrating the utility of AFP as a predictive biomarker.
Anti-Angiogenic Mechanism Research
Characterized VEGF and FGF pathway resistance mechanisms in HCC, informing the rational design of multi-kinase inhibitor combinations and sequencing strategies.
Representative Works 代表性著作
Ramucirumab after Sorafenib in Patients with Advanced Hepatocellular Carcinoma and Elevated AFP (REACH-2)
Lancet Oncology (2019)
First biomarker-selected positive phase III trial in HCC; established ramucirumab standard of care for high-AFP patients.
Molecular Targeted Therapy for Advanced Hepatocellular Carcinoma: Current Status and Future Directions
Journal of Clinical Oncology (2020)
Comprehensive review of HCC systemic therapy landscape, molecular targets, and emerging combination approaches.
🏆Awards & Recognition 奖项与荣誉
📄Data Sources 数据来源
Last updated: 2026-01-15 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Drew M. Pardoll
Johns Hopkins University
Padmanee Sharma
MD Anderson Cancer Center
Naiyer A. Rizvi
Columbia University Irving Medical Center
关注 朱秀轩 的研究动态
Follow Andrew X. Zhu's research updates
留下邮箱，当我们发布与 Andrew X. Zhu（Massachusetts General Hospital / Harvard Medical School）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment